Skip to main content
Top
Published in: Rheumatology International 1/2012

01-01-2012 | Case Report

Dual energy computed tomography for quantification of tissue urate deposits in tophaceous gout: help from modern physics in the management of an ancient disease

Authors: A. Kirstin Bacani, Cynthia H. McCollough, Katrina N. Glazebrook, Jeffrey R. Bond, Clement J. Michet, Jeffrey Milks, Nisha J. Manek

Published in: Rheumatology International | Issue 1/2012

Login to get access

Abstract

Gout has been recognized for centuries but is also a modern day scourge. It is the most common type of inflammatory arthritis in men and appears to be increasing in both incidence and prevalence (Arromdee et al. in J Rheumatol 29(11):2403–2406, 2002). Despite these facts, few advances have been made in the diagnosis and treatment of gout for over 50 years. Difficult cases of gout challenge available therapeutic options. It is only recently that the Food and Drug Administration has approved febuxostat as a treatment option for patients intolerant of allopurinol. We describe a difficult case of tophaceous gout notable for several reasons: utilization of rasburicase as uricolytic treatment to dramatically reduce tissue urate burden; treatment of gout flares with interleukin-1β inhibition; and quantification of tissue urate with novel dual energy computed tomography technology before and after uricolytic therapy.
Literature
1.
go back to reference Loeb JN (1972) The influence of temperature on the solubility of monosodium urate. Arthritis Rheum 15(2):189–192PubMed Loeb JN (1972) The influence of temperature on the solubility of monosodium urate. Arthritis Rheum 15(2):189–192PubMed
2.
go back to reference Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA et al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353(23):2450–2461PubMed Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA et al (2005) Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 353(23):2450–2461PubMed
3.
go back to reference Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A (2002) Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 47(4):356–360PubMed Perez-Ruiz F, Calabozo M, Pijoan JI, Herrero-Beites AM, Ruibal A (2002) Effect of urate-lowering therapy on the velocity of size reduction of tophi in chronic gout. Arthritis Rheum 47(4):356–360PubMed
4.
go back to reference Terkeltaub R (2007) Learning how and when to employ uricase as bridge therapy in refractory gout. J Rheumatol 34(10):1955–1958PubMed Terkeltaub R (2007) Learning how and when to employ uricase as bridge therapy in refractory gout. J Rheumatol 34(10):1955–1958PubMed
5.
go back to reference Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E et al (2001) Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 28(3):577–580PubMed Li-Yu J, Clayburne G, Sieck M, Beutler A, Rull M, Eisner E et al (2001) Treatment of chronic gout. Can we determine when urate stores are depleted enough to prevent attacks of gout? J Rheumatol 28(3):577–580PubMed
6.
go back to reference Richette P, Briere C, Hoenen-Clavert V, Loeuille D, Bardin T (2007) Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol 34(10):2093–2098PubMed Richette P, Briere C, Hoenen-Clavert V, Loeuille D, Bardin T (2007) Rasburicase for tophaceous gout not treatable with allopurinol: an exploratory study. J Rheumatol 34(10):2093–2098PubMed
7.
go back to reference So A, De Smedt T, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9(2):R28PubMed So A, De Smedt T, Revaz S, Tschopp J (2007) A pilot study of IL-1 inhibition by anakinra in acute gout. Arthritis Res Ther 9(2):R28PubMed
8.
go back to reference Johnson TR, Krauss B, Sedlmair M, Grasruck M, Bruder H, Morhard D et al (2007) Material differentiation by dual energy CT: initial experience. Eur Radiol 17(6):1510–1517PubMed Johnson TR, Krauss B, Sedlmair M, Grasruck M, Bruder H, Morhard D et al (2007) Material differentiation by dual energy CT: initial experience. Eur Radiol 17(6):1510–1517PubMed
9.
go back to reference Primak AN, Fletcher JG, Vrtiska TJ, Dzyubak OP, Lieske JC, Jackson ME et al (2007) Noninvasive differentiation of uric acid versus non-uric acid kidney stones using dual-energy CT. Acad Radiol 14(12):1441–1447PubMed Primak AN, Fletcher JG, Vrtiska TJ, Dzyubak OP, Lieske JC, Jackson ME et al (2007) Noninvasive differentiation of uric acid versus non-uric acid kidney stones using dual-energy CT. Acad Radiol 14(12):1441–1447PubMed
10.
go back to reference Takahashi N, Hartman RP, Vrtiska TJ, Kawashima A, Primak AN, Dzyubak OP et al (2008) Dual-energy CT iodine-subtraction virtual unenhanced technique to detect urinary stones in an iodine-filled collecting system: a phantom study. AJR Am J Roentgenol 190(5):1169–1173PubMed Takahashi N, Hartman RP, Vrtiska TJ, Kawashima A, Primak AN, Dzyubak OP et al (2008) Dual-energy CT iodine-subtraction virtual unenhanced technique to detect urinary stones in an iodine-filled collecting system: a phantom study. AJR Am J Roentgenol 190(5):1169–1173PubMed
11.
go back to reference Boers M, Brooks P, Strand CV, Tugwell P (1998) The OMERACT filter for outcome measures in rheumatology. J Rheumatol 25(2):198–199PubMed Boers M, Brooks P, Strand CV, Tugwell P (1998) The OMERACT filter for outcome measures in rheumatology. J Rheumatol 25(2):198–199PubMed
12.
go back to reference Schumacher HR Jr, Becker MA, Palo WA, Streit J, MacDonald PA, Joseph-Ridge N (2005) Tophaceous gout: quantitative evaluation by direct physical measurement. J Rheumatol 32(12):2368–2372PubMed Schumacher HR Jr, Becker MA, Palo WA, Streit J, MacDonald PA, Joseph-Ridge N (2005) Tophaceous gout: quantitative evaluation by direct physical measurement. J Rheumatol 32(12):2368–2372PubMed
13.
go back to reference Perez-Ruiz F, Martin I, Canteli B (2007) Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol 34(9):1888–1893PubMed Perez-Ruiz F, Martin I, Canteli B (2007) Ultrasonographic measurement of tophi as an outcome measure for chronic gout. J Rheumatol 34(9):1888–1893PubMed
14.
go back to reference Schumacher HR, Taylor W, Joseph-Ridge N, Perez-Ruiz F, Chen LX, Schlesinger N et al (2007) Outcome evaluations in gout. J Rheumatol 34(6):1381–1385PubMed Schumacher HR, Taylor W, Joseph-Ridge N, Perez-Ruiz F, Chen LX, Schlesinger N et al (2007) Outcome evaluations in gout. J Rheumatol 34(6):1381–1385PubMed
Metadata
Title
Dual energy computed tomography for quantification of tissue urate deposits in tophaceous gout: help from modern physics in the management of an ancient disease
Authors
A. Kirstin Bacani
Cynthia H. McCollough
Katrina N. Glazebrook
Jeffrey R. Bond
Clement J. Michet
Jeffrey Milks
Nisha J. Manek
Publication date
01-01-2012
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 1/2012
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-009-1295-7

Other articles of this Issue 1/2012

Rheumatology International 1/2012 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.